EGFR and glioblastoma: Currently, amplification/overexpression of epidermal growth factor receptor (EGFR), which occurs in ~52% of patients with primary GBM [6,7,8,9], is the strongest predictor of shorter overall survival [6], and most new therapeutics are targeted to EGFR.